BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study
Reuters
Nov 03
BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study
BridgeBio Pharma Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis (marketed as Attruby™), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM), associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566844-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.